Polymer conjugates as anticancer nanomedicines

Nature Reviews Cancer

Volumn 6, Issue 9, 2006, Pages 688-701

  Duncan, Ruth ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; ALPHA INTERFERON; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; ARGININE DEIMINASE; ASPARAGINASE MACROGOL; CARBOPLATIN; DEXTRAN CAMPTOTHECIN; DEXTRAN DOXORUBICIN; FLUOROURACIL; GEMCITABINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; N (2 HYDROXYPROPYL)METHACRYLAMIDE CAMPOTHECIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE CARBOPLATIN PLATINATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE DIAMINOCYCLOHEXANE PLATINATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE GLYCYLPHENYLALANYLLEUCYLGLYCINE DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE GLYCYLPHENYLALANYLLEUCYLGLYCINE DOXORUBICIN GALACTOSAMINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE PACLITAXEL; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGYLATED GLUTAMINASE; PEGYLATED RECOMBINANT ARGININE DEIMINASE; POLYGLUTAMATE CAMPOTHECIN; POLYMER; PROTHECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLACTIC SHOCK; CLINICAL TRIAL; CONJUGATE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; GENE TARGETING; HEPATIC ARTERY; HUMAN; HYPERSENSITIVITY; KIDNEY CARCINOMA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TOXICITY; MELANOMA; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DESIGN; ENZYMES; HUMANS; MODELS, BIOLOGICAL; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; POLYMERS; PROTEINS;

EID: 33747840618     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1958     Document Type: Review

References (159)

1. Atkins, J. H. & Gershell, L. J. Selective anticancer drugs. Nature Rev. Cancer 1, 645-646 (2002).
2. Huang, P. S. & Oliff, A. Drug-targeting strategies in cancer therapy, Current Opin. Genet. Dev. 11, 104-110 (2001).
3. Moses, M. A., Brem, H. & Langer, R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4, 337-341 (2003).
4. Kamb, A. What's wrong with our cancer models? Nature Rev. Drug Discov. 4, 161-165 (2005).
5. Chabner, B. A. & Roberts, T. G. Timeline - chemotherapy and the war on cancer. Nature Rev. Cancer 5, 65-72 (2005).
6. Tsukagoshi, S. A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10. 8 mg depot). Outline of pre-clinical and clinical studies. Gan To Kagaku Ryoho 29, 1675-1687 (2002).
7. Heyns, C. F., Simonin, M. P., Grosgurin, P., Schall, R. & Porchet, H. C. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 92, 226-231 (2003).
8. Brem, H. et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008-1012 (1995).
9. Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 5, 79-88 (2003).
10. US National Cancer Institute. NIH/NCI Cancer Nanotechnology Plan. US National Cancer Institute [online], http://nano.cancer.gov/ alliance_cancer_nanotechnology_plan.pdf (2004).
11. European Science Foundation. European Science Foundation Forward Look on Nanomedicine. European Science Foundation [online], http://www.esf.org/ publication/196/ESPB23.pdf (2005).
12. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nature Rev. Cancer 5, 161-171 (2005).
13. Duncan, R. Targeting and intracellular delivery of drugs. in: Encyclopedia of Molecular Cell Biology and Molecular Medicine (ed. Meyers, R. A.) 163-204 (Wiley-VCH Verlag, GmbH & Co, Weinheim, Germany, 2005).
14. Damle, N. K. & Frost, P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Phamacol. 3, 386-390 (2003).
15. Milenic, D. E., Brady, E. D. & Brechbiel, M. W. Antibody-targeted radiation cancer therapy. Nature Rev. Drug Disc. 3, 488-498 (2004).
16. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Drug Discov. 2, 750-763 (2002). Excellent description of ligands and technologies explored for tumour targeting. Includes information on antibodies, immunoliposomes, immuno-toxins and immuno-polymer conjugates.
17. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug Discov. 4, 145-160 (2005).
18. Brigger, I., Dubernet, C. & Couvreur, P. Nanoparticles in cancer therapy and diagnosis Adv. Drug Del. Rev. 54, 631-651 (2002).
19. Kattan, J. et al. Phase 1 clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 10, 191-199 (1992).
20. O'Shaughnessy, J. A. et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metatastic breast cancer. Proc. San Antonio Breast Cancer Symposium 1070 (2004).
21. Duncan, R. The dawning era of polymer therapeutics. Nature Rev. Drug Discov. 2, 347-360 (2003).
22. Duncan, R., Dimitrijevic, S. & Evagorou, E. G. The role of polymer conjugates in the diagnosis and treatment of cancer. S. T. P. Pharma Sciences 6, 237-263 (1996).
23. Donaruma, L. G. Synthetic biologically active polymers. Progr. Polym. Sci. 4, 1-25 (1974).
24. Seymour, L. W. Synthetic polymers with intrinsic anticancer activity. J. Bioact. Comp. Polymers 6, 178-216 (1991).
25. Regelson, W. & Parker, G. The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest. 4, 29-42 (1986).
26. Duncan, R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3, 175-210 (1992).
27. Duncan, R. Polymer-anticancer drug conjugates. in Handbook of Anticancer Drug Development (eds Budman, D., Calvert, H. & Rowinsky, E.) 239-260 (Lippincott Williams & Wilkins, Baltimore, 2003). Overview describing the rationale for design and current clinical status of polymer-anticancer conjugates for the first time from the viewpoint of cancer-drug development.
28. Kopecek, J., Kopeckova, P., Minko, T. & Lu, Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61-81 (2000).
29. Harris, J. M. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nature Rev. Drug Discov. 2, 214-221 (2003).
30. Pasut, G., Guiotto, A. & Veronese, F. Protein, peptide and non-peptide drug PEGylation for therapeutic application. Expert Opin. Therap. Patents 14, 859-894 (2004).
31. Yokoyama, M. et al. Polymeric micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J. Cont Rel. 11, 269-278 (1990).
32. Pack, D. W., Hoffman, A. S., Pun, S. & Stayton, P. S. Design and development of polymers for gene delivery. Nature Rev. Drug Discov. 4, 581-593 (2005).
33. Wagner, E. & Kloeckner, J. Gene delivery using polymer therapeutics. Adv. Polymer Sci. 192, 135-174 (2005).
34. Kukowska-Latallo et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65, 5317-5324 (2005).
35. Duncan, R. & Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Del. Rev. 57, 2215-2237 (2005).
36. Maeda, H. & Konno, T. in Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (eds Maeda, H., Edo, K. & Ishida, N.) 227-267 (Springer Verlag, Berlin, 1997).
37. Konno, T. & Maeda, H. in: Neoplasma of the liver (eds Okada, K. & Ishak, K. G.) 343-352 (New York, 1987).
38. Iwai, K., Maeda, H. & Konno, T. Use of oily contrast medium for selective drug targeting to tumour: Enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2114-2121 (1984).
39. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 6, 6387-6392 (1986). Milestone paper identifying for the first time the importance of passive tumour targeting through the EPR effect.
40. Ishii, H. et al. A phase I study of hepatic arterial infusion chemotherapy with zinostatin stimalamer alone for hepatocellular carcinoma. Jap. J. Clin. Oncol. 33, 570-573 (2003).
41. Taguchi, T. et al. Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection Therapy with YM881. Gan To Kagaku Ryoho 18, 1665-1675 (1991).
42. Okusaka, T. et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 5, 276-283 (1998).
43. Abe, S. & Otsuki, M. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. Curr. Med. Chem. Anticancer Agents 2, 715-726 (2002).
44. Davis, F. F. The origin of pegnology. Adv. Drug Del. Rev. 54, 457-458 (2002). Important recent review that describes the pioneering research that opened the field of PEGylation.
45. Delgado, C., Francis, G. E. & Fisher, D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 249-304 (1992).
46. Fuertges, F. & Abuchowski, A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Cont. Rel. 11, 139-148 (1990).
47. Graham, M. L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55, 1293-1302 (2003).
48. Ho, D. H. et al. Clinical pharmacology of polyethylene glycol-asparaginase. Drug Metab. Disposit. 14, 349-352 (1986). Landmark paper describing the first clinical studies involving PEGylated-L-asaparaginase.
49. Kurtzberg, J., Moore, J. O., Scudiery, D. & Franklin, A. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias. Proc. Am. Assoc. Cancer Res. 29, 213 (1988).
50. Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P. & Buchanan, G. R. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96, 1709-1715 (2000).
51. Cheng, P. N. et al. Pegylated recombinant human Arginase (rhArg-peg 5000Mw) has in vitro and in vivo anti-proliferative potential and apoptotic activities in human hepatocellular carcinoma (HCC). Proc. Am. Soc. Clin. Oncol. 96, abstract 3179 (2005).
52. Delman, K. A. et al. Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma. Proc. Am. Soc. Clin. Oncol. 96, abstract 4139 (2005).
53. Yang, Z. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res. 64, 6673-6678 (2004).
54. Katre, N. V., Knauf, M. J. & Laird, W. J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl Acad. Sci. USA 84, 1487-1491 (1987). The first development of a PEGylated cytokine.
55. Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343-346 (1990).
56. Zimmerman, R. J., Aukerman, S. L., Katre, N. V., Winkelhake, J. L. & Young, J. D. Schedule dependency of the antitumour activity and toxicity of polyethylene glycol-modified interleukin-2 in murine tumour models. Cancer Res. 49, 6521-6528 (1989).
57. Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S. & Asano, K. Pharmacokinetics of recombined human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51, 3710-3714 (1991).
58. Molineux, G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr. Pharm. Des. 10, 1235-1244 (2004). Excellent overview of the pioneering work that led to the design and development of PEG-G-CSF.
59. Holmes, F. A., et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 13, 903-909 (2002).
60. Heil, G. et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90, 4710-4718 (1997).
61. Reddy, K. R., Modi, M. W. & Pedder, S. Use of peginterferon α-2a (40KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Del. Rev. 54, 571-586 (2002).
62. Wang, Y.-S. et al. Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications. Adv. Drug Del. Rev. 54, 547-570 (2002).
63. Bukowski, R. et al. Pegylated interferon α-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol. 20, 3841-3849 (2002).
64. Huang, S. F. et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel. Cancer Res. 62, 5720-5726 (2002).
65. Flaherty L., Heilbrun, L., Marsack, C. & Vaishampayan U. N. Phase II trial of pegylated interferon (Peg-Intron) and thalidomide (Thal) in pretreated metastatic malignant melanoma. Proc. Am. Soc Clinical Oncol. 7562 (2005).
66. Groves, M. D. et al. A phase II study of temozolomide plus pegylated interferon α-2b for recurrent anaplastic glioma and glioblastoma multiforme. Proc. Am. Soc Clinical Oncol. 1519 (2005).
67. Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polymer Sci. Polymer Symp. 51, 135-153 (1975). Landmark paper that stimulated the field of polymer-anticancer conjugates.
68. Duncan, R. N-(2-Hydroxypropyl)methacrylamide copolymer conjugates. in: Polymeric Drug Delivery Systems (ed. Kwon, G. S.) 1-92 (Marcel Dekker, New York, 2005)
69. O'Hare, K. B., Duncan, R., Strohalm, J., Ulbrich, K. and Kopeckova, P. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: In vitro and in vivo evaluation against murine melanoma. J. Drug Targeting 1, 217-229 (1993).
70. Low, P. S. and Antony, A. C. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug Del. Rev. 56, 1055-1058 (2004).
71. Brocchini, S. & Duncan, R. Pendent drugs, release from polymers. in Encyclopeadia of Controlled Drug Delivery (ed. Mathiowitz, E.) 786-816 (John Wiley & Sons, New York, 1999). Comprehensive review citing all of the studies involved in the pioneering research of many different polymer conjugates.
72. Rihova, B. Biocompatibility of biomaterials: haematocompatibility, immunocompatibility, and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv. Drug Del. Rev. 21, 157-176 (1996).
73. Danauser-Reidl, S. et al. Phase-I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs 11, 187-195 (1993). First clinical evaluation of a dextran-drug conjugate.
74. Kumazawa, E. & Ochi, Y. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models. Cancer Sci. 95, 168-175 (2004).
75. Takimoto, C. H. M. et al. A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas. Proc. Am. Soc. Clin. Oncol. 22, 130 (abstr 522) (2003).
76. Greenwald, R. B. et al. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Del. Rev. 55, 217-250 (2003).
77. Rowinsky, E. K. et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. 21, 148-157, (2003).
78. 125I-labelled poly(vinylpyrrolidone) on its pinocytosis by rat visceral yolk sacs and rat peritoneal macrophages. Biochem. J. 196, 49-55 (1980).
79. Seymour, L. W. et al. Effect of molecular weight (MW) of N-(2-hydroxypropyl) methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mat. Res. 21, 1341-1358 (1987).
80. Seymour, L. W. et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31, 766-770 (1995).
81. Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanova, P. & Kopecek, J. Degradation of side-chains of N-(2-hydrox ypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Reps 2, 1041-1046 (1983).
82. Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanova, P. and Kopecek, J. Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side chains in poly [N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184, 1997-2008 (1984). Experiments involving in vitro cell culture led to the discovery that thiol-dependent proteases were important targets for the design of peptide linkers.
83. Duncan, R., Cable, H. C., Rejmanova, P., Kopecek, J. & Lloyd, J. B. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl) methacrylamide copolymers. Biochim. Biophys Acta 799, 1-8 (1984).
84. McCormick, L. A., Seymour, L. C. W., Duncan, R. & Kopecek, J. Interaction of a cationic N-(2-hydroxypropyl) methacrylamide copolymer with rat visceral yolk sacs culture in vitro and rat liver in vivo. J. Bioact. Compat. Polymers 1, 4-19 (1986).
85. Duncan, R., Kopecek, J., Rejmanova, P. & Lloyd, J. B. Targeting of N-(2-hydroxypropyl) methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta 755, 518-521 (1983).
86. Seymour, L. W. et al. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636-641 (1994).
87. Duncan, R. et al. Preclinical evaluation of polymer-bound doxorubicin. J. Cont. Rel. 19, 331-346 (1992). Landmark paper describing the preclinical and in vivo anti-tumour studies for HPMA copolymer-doxorubicin that paved the way for clinical testing of anticancer drug conjugates.
88. Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug-polymer conjugates. Clin. Cancer Res. 5, 83-94 (1999). The first clinical study to evaluate a synthetic polymer-drug conjugate.
89. Thomson, A. H. et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br. J. Cancer 81, 99-107 (1999).
90. Cassidy, J. PK1: Results of Phase I studies. Proc 5th Intl Symp on Polymer Therapeutics: From Laboratory to Clinical Practice, Cardiff, UK p 20 (2000).
91. Seymour, L. W. et al. Hepatic drug targeting: Phase I evaluation of polymer bound doxorubicin. J. Clin. Oncol. 20, 1668-1676 (2002). The first clinical study describing a targeted polymer-anticancer drug conjugate.
92. Julyan, P. J. et al. Preliminary clinical study of the distribution of HPMA copolymer-doxorubicin bearing galactosamine. J. Cont. Rel. 57, 281-290 (1999).
93. Meerum Terwogt, J. M. et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12, 315-323 (2001).
94. Schoemaker, N. E. et al. A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. Br. J. Cancer 87, 608-614 (2002).
95. Bissett, D. et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer, 91, 50-55 (2004).
96. Wachters, F. M. et al. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br. J. Cancer 90, 2261-2267 (2004).
97. Sarapa, N. et al. Targeted delivery and preferential uptake in solid cancer of MAG-CPT, a polymer bound prodrug of camptothecin - a trial in patients undergoing surgery for colorectal carcinoma. Cancer Chemother. Pharmacol. 52 424-430 (2003).
98. Gianasi, E. et al. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Targeting 10, 549-556 (2002).
99. Rademaker-Lakhai, J. M. et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. 10, 3386-3395 (2004).
100. Rice, J. R., Stewart, D. R. & Nowotnik, D. P. Enhanced antitumour activity of a new polymer-linked DACH-platinum complex. Proc. Am. Assoc. Cancer Res. 93, (2002).
101. Rihova, B. et al. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Cont. Rel. 91, 1-16 (2003).
102. Li, C. et al. Complete regression well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 58, 2404-2409 (1998). Wallace, Li et al. were the pioneers who designed and established the basis for PGA-paclitaxel clinical development.
103. Singer, J. W. et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 519, 81-99 (2003).
104. Singer, J. W. et al. Paclitaxel poliglumex (XYOTAX; CT-2103) [XYOTAX™]: an intracellularly targeted taxane. Anticancer Drugs 16, 243-254 (2005).
105. Singer, J. W. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J. Control. Rel. 109, 120-126 (2005).
106. Shaffer, S. A. et al. Proteolysis of Xyotax™ by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS. Eur. J. Cancer 38 (Suppl.), 428 (2002).
107. Todd, R. et al. Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate. Proceedings of the AACR-NCI-EORTC 12th International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Development, and Clinical Validation (2001).
108. Langer, C. J. CT-2103: A novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin. Lung Cancer. 6 (Suppl. 2), S85-S88 (2004).
109. Langer, C. J. et al. Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study. Proc. Am. Soc. Clin. Oncol. 96, abstract LBA7011 (2005).
110. Cell Therapeutics. Improving Outcomes in PS2 Patients: Results of the XYOTAX™ Phase III STELLAR Trials. 11th World Congress on Lung Cancer, Barcelona, Spain July (2005). Landmark paper showing gender differences in the activity of a polymer-drug conjugate designed for thiol-protease activation
111. Socinski, M. XYOTAX in NSCLC and other solid tumors. Emerging evidence on biological sex differences: is gender-specific therapy warranted? Chemotherapy Foundation XXIII Symposium Innovative Cancer Therapy for Tomorrow, Mount Sinai November (2005).
112. Kremer, M., Judd, J., Rifkin, B., Auszmann, J., Oursler, M. J. Estrogen modulation of osteoclast lysosomal-enzyme secretion. J. Cellular Biochem. 57, 271-279 (1995).
113. Bhatt, R. et al. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem. 46, 190-193 (2003).
114. Springett, G. M. et al. Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. J. Clin. Oncol. 22 (Suppl.), S3127 (2004).
115. Sat, Y. N. et al. Comparison of vascular permeability and enzymatic activation of the polymeric prodrug HPMA copolymer-doxorubicin (PK1) in human tumour xenografts. Proc. Am. Assoc. Cancer Res. 90, 41 (1999).
116. St'astny, M., Strohalm, J., Plocova, D., Ulbrich, K., Rihova, B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 35, 459-466 (1999).
117. Malugin, A., Kopeckova, P. & Kopecek J. HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian cancer cells by a Fas-independent pathway. J. Cont. Rel. 91, 254 (2003).
118. Duncan, R. et al. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J. Cont. Rel. 16, 121-136 (1991).
119. Duncan, R. et al. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers, 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Cont. Rel. 10, 51-63 (1989).
120. Gianasi, E. et al. HPMA copolymer platinates as novel antitumor agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer 35, 994-1002 (1999).
121. Minko, T., Kopeckova, P. & Kopecek, J. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin. Macromol. Symp. 172, 35-37 (2001).
122. Kovar, L. et al. The effect of HPMA copolymer-bound doxorubicin conjugates on the expression of genes involved in apoptosis signaling. J. Cont. Rel. 91, 247-248 (2003).
123. Rihova, B. et al. Acquired and specific immunological mechanisms co-responsible for efficacy of polymerbound drugs. J. Cont. Rel. 78, 97-114 (2002).
124. Rihova, B. et al. Drug-HPMA-HuIg conjugates effective against human solid cancer. Adv. Expt Med. Biol. 519, 125-143 (2003).
125. Nemunaitis, J. J. et al. Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): preliminary data. Proc. Am. Soc. Clin. Oncol. 96, Abstract 7230 (2005).
126. Markman, M. Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103. J. Exp. Ther. Oncol. 4, 131-136 (2004).
127. Sabbatini, P. et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 22, 4523-4531 (2004)
128. Herzog, T., Barret, R. J., Edwards, R. &. Oldham, F. B. Phase II study of paclitaxel poliglumex (PPX) / carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma. Proc. Am. Soc. Clin. Oncol. 96, Abstract 5012 (2005).
129. Li, C. et al. Tumour irradiation enhances the tumour-specific distribution of poly(L-glutamic)-conjugates paclitaxel and its antitumour efficacy. Clinical Cancer Res. 6, 2829-2834 (2000)
130. Dipetrillo, T. A. et al. Paclitaxel poliglumex (PPX) and concurrent radiation for treatment of patient s with esophageal or gastric cancer: a dose-ranging study. Proc. Am. Soc. Clin. Oncol. 96, abstract 4065 (2005).
131. Krinick, N. L. et al. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed. 5, 303-324 (1994).
132. Shiah, J.-G. et al. Combination chemotherapy and photodynamic therapy of targetable N-2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e6-OV-TL16 antibody immunoconjugates. J. Control. Rel. 74, 249-253 (2001).
133. Vicent, M. J., Greco, F., Nicholson, R. I. & Duncan, R. Polymer-drug conjugates as a novel combination therapy for the treatment of hormone-dependent cancers. Angew. Chem. Int. Ed. 44, 2-6 (2005).
134. Duncan, R., Vicent, M. J., Greco, F. & Nicholson, R. I. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocrine-Rel. Cancer 12 (Suppl. 1), S189-S199 (2005)
135. Greco, F, Vicent, M. J., Penning, N. A., Nicolson, R. I. & Duncan, R. (2005) HPMA-copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J. Drug Targeting 13, 459-470 (2005).
136. Sawhney, R., Brescia, F., Keane, T., Clarke, H. & Chaudhary, U. B. Phase II trial of pegylated Interferon α-2b, GM-CSF, and thalidomide in metastatic progressive renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 96, abstract 4800 (2005).
137. Unger, C. et al. Phase I dose escalating study of PEG-PGA and DON: A new amino acid depleting anti cancer drug approach. Proc. Am. Soc. Clin. Oncol. abstract 3130 (2005).
138. Fang, H., Sawa, T., Akaike, T. & Maeda, H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 62, 3138 -3143 (2002).
139. Satchi, R., Connors, T. A. & Duncan, R. PDEPT: Polymer directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070-1076 (2001).
140. Satchi-Fainaro, R., Hailu, H., Davies, J. W., Summerford, C. & Duncan, R. PDEPT: Polymer directed enzyme prodrug therapy: II. HPMA copolymer-β-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconj. Chem. 14, 797-804 (2003).
141. Satchi-Fainaro, R. et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Med. 10, 225-261 (2004). Landmark paper describing the first polymer antiangiogenic conjugate.
142. Satchi-Fainaro, R. et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate. Cancer Cell 7, 251-261 (2005).
143. Satchi-Fainaro, R. & Duncan, R. (Eds) Polymer therapeutics I. Adv. Polymer. Sci. 192, 1-204 (2005).
144. Satchi-Fainaro, R. and Duncan R. (Eds.) Polymer therapeutics II. Adv. Polymer Sci.193, 1-228 (2006).
145. Malik, N., Evagorou, E. G. & Duncan, R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10, 767-776 (1999).
146. Baker, J. R. et al. The synthesis and testing of anticancer therapeutic nanodevices. Biomed. Microdevices 3, 61-69 (2001).
147. Gillies, E. R. and Frechet, J. M. Dendrimers and dendritic polymers in drug delivery, Drug Discov. Today 10, 35-43 (2005).
148. Kochendoerfer, G. G. et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299, 884-887 (2003).
149. Shibata, H. et al. Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window. Clin. Cancer Res. 15, 8293-8300 (2004).
150. Zhang, N., Khawli, L. A., Hu, P. & Epstein, A. L. The generation of a novel Rituximab Polymer which leads to CD20 hyper-crosslinking-induced apoptosis in nonhodgkin's Lymphomas. Proc. Am. Assoc. Cancer Res. 96, abstract 6144 (2005).
151. Dharap, S. S. et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl Acad. Sci. USA 102, 12962-12967 (2005).
152. Kataoka, K. et al. Block copolymer micelles as vehicles for drug delivery. J. Cont. Rel. 24, 119-132 (1993)
153. Bae, Y. et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconj. Chem. 16, 122-130, (2005).
154. Danson, S. et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90, 2085-2091 (2004). The first clinical studies using a polymeric micelle.
155. Washart, M. L. et al. Phase I dose escalation study of a polymeric micellar formulation of paclitaxel in patients (pts) with refractory non-hematologic cancer. Proc. Am. Soc. Clin. Oncol 96, abstract 2088 (2005).
156. De Duve, C. et al. Lysosomotropic agents. Biochem. Pharmacol. 23, 2495-2531 (1974).
157. Ulbrich, K. & Subr, V. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. 23, 1023-1050 (2004).
158. Lloyd, J. B. The lysosome/endosome membrane: a barrier to polymer-based drug delivery. Macromol. Symp. 172, 29-34 (2001).
159. Minko, T., Kopeckova, P., Pozharov, V. & Kopecek, J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Cont. Rel. 54, 223-233 (1998).